Philadelphia, PA, August 25, 2025. Strados Labs, a medical technology company focused on improving surveillance of respiratory diseases, is proud to announce a series of ongoing research collaborations in 2025 with leading academic institutions across the United States. These investigator-led studies aim to evaluate how continuous, objective respiratory monitoring with the RESP® Biosensor may improve clinical outcomes across a range of patient populations and care settings.
The RESP® Biosensor, an FDA 510(k) cleared and CE marked wearable respiratory device, continuously captures patients’ lung sounds including cough, wheeze, and crackles in hospital inpatient settings and at home. The novel wearable device is being actively studied in both adult and pediatric populations to understand how monitoring of lung sounds and additional parameters may add value in patient care.
Selected 2025 Active Research Collaborations
Improving Pulmonary Edema Detection in ICU Patients
In a collaboration with Beth Israel Deaconess Medical Center, researchers are evaluating whether lung sounds captured by the RESP Biosensor can aid in the early detection of pulmonary edema among critically ill patients on mechanical ventilation. The single-center, prospective study will compare biosensor data to conventional methods such as daily chest X-rays and fluid balance tracking. By identifying abnormal lung sounds that may precede clinical signs of pulmonary edema, the study aims to support earlier and more proactive interventions in the ICU.
Expanding Home Monitoring for Cystic Fibrosis
Strados Labs is collaborating with Rutgers Robert Wood Johnson Medical School and RWJBarnabas Health to evaluate the use of the RESP Biosensor in adults living with cystic fibrosis (CF). This pilot study will enroll up to 100 participants to determine whether lung sounds collected at home correlate with disease severity, patient-reported outcomes, and lung function measures such as FEV1. The study explores the feasibility of integrating continuous, low-effort monitoring into daily life for patients at risk of pulmonary exacerbations, potentially improving self-management and remote care.
Exploring Wearable Monitoring in Pediatric Critical Care
At a leading pediatric hospital in the Southeast, Strados Labs is supporting a study focused on critically ill children admitted to the pediatric intensive care unit (PICU). The study will evaluate the feasibility of the RESP® Biosensor to continuously monitor cardiopulmonary status in children with conditions such as asthma, bronchiolitis, and congenital heart disease. By comparing biosensor-derived metrics to traditional clinician assessments, the study seeks to validate whether passive, objective signals can enhance the accuracy and frequency of pediatric respiratory evaluations.
Advancing Early Detection of Respiratory Decline in Bronchiolitis
In a pilot study at a renowned children’s hospital in the Northeast, researchers are assessing the RESP Biosensor’s ability to continuously monitor lung sounds in infants hospitalized with bronchiolitis. The goal is to identify whether abnormal sounds such as wheeze or crackles correlate with clinical deterioration and precede observable changes in oxygen saturation or respiratory support. As bronchiolitis is the leading cause of infant hospitalization in the U.S., continuous monitoring may offer clinicians a new tool to support earlier interventions and reduce complications.
Four Studies, One Goal
“We are proud to collaborate with these forward-thinking clinical teams across the country,” said Nick Delmonico, CEO & Co-founder of Strados Labs. “Each of these studies shares a common goal: to increase our understanding of the potential of continuous, wearable lung sound monitoring in offering earlier insights, guiding interventions, and ultimately improving patient care across several patient populations.”
As respiratory conditions remain a leading cause of hospitalization and health decline worldwide, Strados Labs continues to expand innovation in remote and real-world respiratory monitoring. These studies represent a major step forward in understanding the clinical value of wearable technologies and expanding their use in both research and patient care.
About Strados Labs
Strados Labs is a medical technology company focused on improving the lives of patients with respiratory diseases using innovative technology. Enabling real-world monitoring of lung health, Strados Labs’ RESP Biosensor allows clinicians to continuously measure patients’ lung sounds including cough and wheeze that can indicate an exacerbation or reduced quality of life. The technology is also used to assist drug developers in assessing treatment response in clinical trials. The RESP Biosensor has two FDA 510(k) clearances, a CE mark, and is backed by multiple awards and clinical publications. Strados Labs is privately owned and based in Philadelphia, PA.
For more information, visit Stradoslabs.com or follow us on LinkedIn and X.